MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

94.31
+3.09
+3.39%
After Hours: 94.31 0 0.00% 16:41 04/07 EDT
OPEN
92.95
PREV CLOSE
91.22
HIGH
95.91
LOW
91.62
VOLUME
808.80K
TURNOVER
--
52 WEEK HIGH
119.65
52 WEEK LOW
71.85
MARKET CAP
8.70B
P/E (TTM)
285.96
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBIX stock price target is 119.20 with a high estimate of 132.00 and a low estimate of 104.00.

EPS

NBIX News

More
  • These stocks, including Amazon and Hasbro, can weather the pandemic, analysts say
  • CNBC.com · 3d ago
  • Neurocrine Biosciences Provides COVID-19 Business Update
  • PR Newswire · 4d ago
  • Neurocrine Bio suspends enrollment in key study amid COVID-19
  • Seeking Alpha - Article · 4d ago
  • Neurocrine Bio updates business amid COVID-19
  • Seeking Alpha - Article · 4d ago

Industry

Biotechnology & Medical Research
-2.20%
Pharmaceuticals & Medical Research
-1.62%

Hot Stocks

Symbol
Price
%Change

About NBIX

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.